Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Edgewise Therapeutics (EWTX) Enterprise Value (2021 - 2026)

Edgewise Therapeutics has reported Enterprise Value over the past 7 years, most recently at -$499.6 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$499.6 million for Q1 2026, down 14.48% from a year ago — trailing twelve months through Mar 2026 was -$499.6 million (down 14.48% YoY), and the annual figure for FY2025 was -$61.1 million, down 46.76%.
  • Enterprise Value reached -$499.6 million in Q1 2026 per EWTX's latest filing, down from -$61.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$22.0 million in Q4 2022 and bottomed at -$594.0 million in Q2 2025.
  • Median Enterprise Value over the past 5 years was -$248.4 million (2022), compared with a mean of -$229.7 million.
  • The largest annual shift saw Enterprise Value skyrocketed 90.77% in 2024 before it tumbled 1341.98% in 2025.
  • Over 5 years, Enterprise Value stood at -$22.0 million in 2022, then crashed by 291.47% to -$86.1 million in 2023, then skyrocketed by 51.61% to -$41.7 million in 2024, then tumbled by 46.76% to -$61.1 million in 2025, then crashed by 717.03% to -$499.6 million in 2026.
  • Business Quant data shows Enterprise Value for EWTX at -$499.6 million in Q1 2026, -$61.1 million in Q4 2025, and -$46.0 million in Q3 2025.